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Purpose: The aim of this study was to determine whether biphasic calcium phosphate (BCP) bone substitute with two differ-
ent concentrations of Escherichia coli-expressed recombinant human bone morphogenetic protein 2 (ErhBMP-2) enhances 
new bone formation in a standardized rabbit sinus model and to evaluate the concentration-dependent effect of ErhBMP-2.
Methods: Standardized, 6-mm diameter defects were made bilaterally on the maxillary sinus of 20 male New Zealand white 
rabbits. Following removal of the circular bony windows and reflection of the sinus membrane, BCP bone substitute without 
coating (control group) was applied into one defect and BCP bone substitute coated with ErhBMP-2 (experimental group) was 
applied into the other defect for each rabbit. The experimental group was divided into 2 subgroups according to the concen-
tration of ErhBMP-2 (0.05 and 0.5 mg/mL). The animals were allowed to heal for either 4 or 8 weeks and sections of the aug-
mented sinus and surrounding bone were analyzed by microcomputed tomography and histologically. 
Results: Histologic analysis revealed signs of new bone formation in both the control and experimental groups with a statis-
tically significant increase in bone formation in experimental group 1 (0.05 mg/mL ErhBMP-2 coating) after a 4-week healing 
period. However, no statistically significant difference was found between experimental group 1 and experimental group 2 (0.5 
mg/mL ErhBMP-2 coating) in osteoinductive potential (P<0.05).
Conclusions: ErhBMP-2 administered using a BCP matrix significantly enhanced osteoinductive potential in a standardized 
rabbit sinus model. A concentration-dependent response was not found in the present study.
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INTRODUCTION
Recombinant human bone morphogenetic protein-2 (rh-
BMP-2) derived from BMP gene transfected Escherichia coli 
(ErhBMP-2) has been developed and considered to be a pos-
sible alternative to rhBMP-2 derived from the BMP gene 
Received:  Jun. 10, 2012;  Accepted:  Aug. 3, 2012
*Correspondence:  Sungtae Kim 
Department of Periodontology, Dental Research Institute, Seoul National University School of Dentistry, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea
E-mail: kst72@snu.ac.kr, Tel: +82-2-2072-4712, Fax: +82-2-744-0051
Journal of Periodontal
& Implant ScienceJPISOsteogenic potential of BCP coated with different concentration of Erh-BMP2120
transfected Chinese hamster ovary cells (CrhBMP-2) [1-4]. 
Recently ErhBMP-2, which showed biological activity 
through the post-translational refolding technique, has been 
reported to induce ectopic bone formation and noticeably 
enhanced new bone formation in a dose-dependent manner 
[2,5]. A supraphysiologic dose of BMP is usually applied in 
clinical situations to induce osteogenesis effectively [6]. 
However, there exist several adverse effects such as ectopic 
bone formation, cyst-like bone void formation, and soft tis-
sue swelling [7-9]. Therefore, if possible, a lower dose of BMP 
should be applied to prevent these possible adverse effects. 
Biphasic calcium phosphate (BCP) bone substitute has been 
widely used as a defect-filling material for periodontal and 
dental implant surgery and has shown favorable clinical out-
comes [10]. The BCP bone substitute used in the present study 
is hydroxyapatite (HA) coated with β-tricalcium phosphate 
(β-TCP) in a 7:3 ratio that showed an ideal BCP degradation 
rate in previous studies [10,11]. This BCP is usually used as an 
osteoconductive matrix that maintains space for new bone 
formation. It also has osteoinductive potential which is limit-
ed but higher than than pure HA or β-TCP [11,12]. The com-
bination of BCP as osteoconductive matrix with osteogenic 
cells and osteoinductive growth factors such as BMP may be 
even more effective in bone formation than autograft, the 
latter of which has, until now, been considered the gold stan-
dard of bone substitutes [13]. There exist micro- and macro-
pores in the BCP bone substitute surface. Micropores are 
known to be sites of nucleation for biological apatite precipi-
tation [14]. Macropores are potential spaces for new bone 
maturation, and possible sites for entrapment of BMP-2 [15].
There have been studies in which BMP-2 was applied to 
surgical defects in animal models. Collagen membrane, col-
lagen block, and particulated or block type BCP bone substi-
tute have been applied as a matrix for BMP-2 [16-18]. Colla-
gen is the most often applied carrier. However, considering 
its poor structural integrity and minimal osteoconductivity, 
collagen cannot be an ideal matrix for BMP-2 [16,17]. BCP 
might be a better osteoconductive matrix for BMP-2. In ad-
dition, BCP coated with BMP-2 could be better than BCP 
moistened with diluted BMP-2 because of the inaccurate 
dosing and uncontrolled flow with the moistening method 
[18,19]. The purpose of this study was to evaluate the differ-
ence in bone forming ability of BCP coated with two different 
concentrations (0.5 mg/mL and 0.05 mg/mL) of ErhBMP-2 in 
rabbit sinus defects. 
MATERIALS AND METHODS 
Animals
Twenty male New Zealand white rabbits (40 maxillary sinus 
defects) weighing 2.5 to 3.0 kg were used for the experimen-
tal model (Table 1). The positioning of the window on the 
maxillary sinus of the rabbits followed the procedure of Asai 
et al. [20]: 20 mm anterior to the nasofrontal suture line and 
10 mm lateral to the midline. Animal selection, management, 
surgical protocol, and preparation followed routines approved 
by the Institutional Animal Care and Use Committee of Yon-
sei Medical Center, Seoul, Korea.
Study design
Standardized, bilateral, circular, transosseous defects 6 mm 
in diameter were made on the maxillary sinus (Figs. 1 and 2).
Preparation of ErhBMP-2 coated BCP 
Prior to the surface coating, the ErhBMP-2 was produced at 
the Cowell Medi Implant (Busan, Korea). Nonglycosylated 
rhBMP-2 was obtained in the form of inclusion bodies and 
Table 1. Study design.
Group Material Experimental period Defect no.
Control OSTEONTM 4 weeks, 8 weeks 20
Experimental 1 ErhBMP-2 0.05 mg/mL 4 weeks, 8 weeks 10
Experimental 2 ErhBMP-2 0.5 mg/mL 4 weeks, 8 weeks 10
ErhBMP-2: Escherichia coli-expressed recombinant human bone morphogenetic 
protein 2.
Figure 1. Maxillary sinus defects in the rabbit. Standardized, bilater-
al, circular, transosseous windows were prepared on the maxillary 
sinus using a 6-mm diameter trephine bur with the pin inserted.
Figure 2. Schematic diagram of trephine bur (outer diameter 8.0 mm, 
inner diameter 6.0 mm, depth 1.5 mm).
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was refolded in vitro into the active dimer form [11]. Surface 
coating was performed to combine HA, one of the constitu-
ents of BCP (Osteon, Dentium, Korea), with ErhBMP-2. Ini-
tially, the hydroxyl group of hydroxyapitite was linked with 
3-aminopropyl triethoxysilane (APTES) (Sigma-Aldrich Co., 
St. Louis, MO, USA), a silane coupling agent, then followed 
by linkage with N-succinimidyl 3-maleimidopropionate (N-
SMP) (Sigma-Al drich Co.) and then ErhBMP-2. This proce-
dure can be sum marized as a three-step reaction procedure: 
1) silanization with APTES, 2) cross-linking with N-SMP, 3) 
combining N-SMP with ErhBMP-2. Two different concen-
trations of ErhBMP-2 (0.5 and 0.05 mg/mL) were made after 
the coating procedure. ErhBMP-2-coated BCP was lyophi-
lized. The solution was frozen cooled down to -43°C. The 
formu lations were maintained at this temperature for 3 
hours, after which they were dried in a condenser at -40°C 
(primary dry ing) and kept in a pressure chamber at 5 mTorr 
for 2 hours. Secondary drying was performed on a shelf us-
ing the follow ing sequence: -20°C for 4 hours, -10°C for 4 
hours, 0°C for 2 hours, and 20°C for 20 hours. After the ly-
ophilizing procedure, the ErhBMP-2-coated BCP was steril-
ized with ethylene oxide gas in a gas sterilizer (Steri-Vac 400B, 
3M, St. Paul, MN, USA) at 29°C for 5 hours, which was report-
ed as the ideal sterilization protocol to avoid reducing osteo-
inductive activity [21].
Surgical procedure
For all of the surgical procedures involved in the study, the 
animals were first sedated with a mixture of ketamine hy-
drochloride (Ketalar, Yuhan, Seoul, Korea) and xylazine (Rum-
pun, Bayer Korea Ltd., Seoul, Korea) via an intramuscular in-
jection. After the isolation of the surgical site by shaving and 
sterilizing with a povidone-iodine solution, infiltration anes-
thesia with 2% lidocaine (with 1:100,000 epinephrine) was 
also administrated to the surgical sites on the nasal bone. A 
straight incision along the sagittal midline on the nasal bone 
was then made followed by a full-thickness flap including 
the skin and the elevation of the periosteum laterally. Stan-
dardized, bilateral, circular, transosseous windows were pre-
pared on the maxillary sinus using a trephine bur 6 mm in 
diameter under copious irrigation with saline. The pin was 
inserted at the point where the sagittal midline met the 
imaginary line that connected the right and left windows in 
order to indicate the reference point for micro computed to-
mography (CT) analysis as well as for preparation of the 
specimen. The trephined bony disk was carefully removed 
and the experimental and control treatments with grafting 
materials were applied to the windows accordingly. 
After the grafting materials was placed, the periosteum was 
re-positioned over the windows on each side followed by su-
turing of the skin/periosteum flap with 40 Monosyn (glyconate 
absorbable monofilament, B-Braun, Aesculap, Center Valley, 
PA, USA), which was removed after 7 days. The animals were 
allowed a healing period of either 4 or 8 weeks postopera-
tively and sacrificed accordingly by euthanasia. 
Radiographic analysis: Micro-CT
After obtaining block sections including the augmented si-
nus and the surrounding bone, each block section was fixed 
in 10% buffered formalin for 10 days and scanned using mi-
cro-CT (SkyScan 1076, SkyScan, Aartselaar, Belgium) at a res-
olution of 35 μm (100 kV and 100 μA). The scanned data set 
were analyzed and the area of interest was reconstructed with 
a CT analyzer program (SkyScan). After a 3D-reconstructed 
image of the maxillary sinus and supporting bone was visu-
alized using a data viewer program, the CT volume, the max-
imum augmented height (MAH), and the deepest depth of 
the defect (DDD) [16] were measured on the coronally sec-
tioned images; MAH was measured linearly on the cross-
sectional image. The CT volume was calculated from the per-
centage of window closure where new bony formation or re-
maining grafting materials could be seen. MAH was mea-
sured linearly on the cross-sectional image whereas the DDD 
was measured from the imaginary line through the original 
bone to the bottom of the bony crater.
Histological analysis 
Following decalcification in 5% formic acid for 14 days, all 
specimens were embedded in paraffin and sliced coronally 
into sections about 5 μm thick along the center of the aug-
mented sinus. The 2 most-central sections were selected and 
stained with hematoxylin and eosin (H&E) for the light mi-
croscopic examination (BX50, Olympus Co., Tokyo, Japan).
Histometric analysis 
Computer-assisted histometric analysis was performed us-
ing an automated image-analysis system (Image-Pro Plus, 
The Proven Solution, Media Cybernetics Inc., Silver Spring, 
MD, USA). Two parameters were measured and calculated as 
follows: 
Newly formed bone area (NB%)=newly formed area/total 
augmented bone area×100
Remaining grafts area (RG%)=remaining graft area/total 
augmented bone area×100
Statistical analysis
The statistical analysis regarding micro-CT data and histo-
morphometric measurement of the samples was performed 
using a SPSS ver. 15.0 (SPSS Inc., Chicago, IL, USA). The Mann-
Whitney U test was used to compare differences between 
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control group and experimental group (groups 1 and 2) and 
differences according to time of healing. The level of statisti-
cal significance was set at P<0.05, and the data were present-
ed as means±standard deviation values.
RESULTS
Radiographic and histometric analysis
In the 4-week healing groups, new bone formation (%) was 
greater in experimental group 1 than in the control group 1 
(P<0.05). The remaining graft material (%) was less in experi-
mental group 1 than in the control group 1 (P<0.05). No sig-
nificant difference was found between experimental group 1 
and experimental group 2 in new bone formation or remain-
ing graft (Table 2).
In the 8-week healing groups, there was no statistical dif-
ference in new bone formation, remaining graft, or CT vol-
ume between experimental group 1 and experimental group 
2. However, new bone formation (%) was greater in experi-
mental group 2 than the control group 2 (P<0.05). There was 
no difference in the remaining graft between experimental 
group 1 and the control group 1. The CT volume was greater 
in the control group 1 than experimental group 1 (P<0.05) 
and the MAH was greater in experimental group 1 than in 
experimental group 2 (Table 2).
Histologic findings 
The histologic findings revealed that both experimental 
group 1 and group 2 showed a mixture of newly formed bone 
from the surgically created defects and newly formed bone 
originating from bone graft materials. As shown in Figs 3-6, 
newly formed bone from the surgically created defect is par-
ticularly distinguishable as it is shown to be more mature in 
contrast to newly formed bone that originated from bone 
Table 2. Measurements in standardized rabbit sinus model.
Time Group Material New bone (%) Remaining graft (%) CT volume MAH DDD
4 weeks
Control 1 OSTEONTM 21.41±3.16 30.83±1.60 41.31±8.37 5.78±0.44 0.54±0.50
Experimental 1 ErhBMP-2 (0.05 mg/mL) 30.49±7.88 23.24±2.82 24.93±4.97 6.42±0.79 1.16±0.85 
Control 2 OSTEONTM 24.11±5.00 29.34±6.72 28.62±2.67 4.83±0.88 1.20±0.53
Experimental 2 ErhBMP-2 (0.5 mg/mL) 27.29±5.62 29.20±4.68 23.32±1.86 5.21±1.00 0.95±0.65
8 weeks
Control 1 OSTEONTM 28.33±3.89 30.27±4.33 37.57±8.53 7.08±0.62 0.96±0.75
Experimental 1 ErhBMP-2 (0.05 mg/mL) 24.83±10.36 28.09±3.18 25.47±4.79 7.00±1.73 0.62±0.40
Control 2 OSTEONTM 22.56±2.14 27.29±6.05 26.57±4.74 5.81±1.07 0.84±0.24
Experimental 2 ErhBMP-2 (0.5 mg/mL) 29.22±3.16 28.16±4.17 23.66±2.61 5.20±0.95 0.71±0.44
Values are presented as mean±standard deviation.
CT: computed tomography, MAH: maximum augmented height, DDD: deepest depth of the defect, ErhBMP-2: Escherichia coli-expressed recombinant human bone 
morphogenetic protein 2.
Figure 3. Histologic findings of experimental group 1 (0.05 mg/mL ErhBMP-2) at 4 weeks. (A) There appeared to be a mixture of newly formed 
bone from the surgically created defect and newly formed bone originating from bone graft materials. Newly formed bone from the surgical-
ly created defect is shown to be more mature whereas newly formed bone from the bone graft materials is still undergoing the mineraliza-
tion process (×12.5). (B) Defect margin area: The arrowheads indicate the margin of the surgically created defect. The white asterisk indicates 
newly formed bone assumed to have originated from the defect margin (×50). (C) The Schneiderian membrane: The black asterisk indicates 
newly formed bone assumed to have originated from graft materials (×50). Note that immature woven bone is evident here in contrast to 
mature lamellar bone as indicated by the white asterisk in Fig. 3B. (D) Middle area: Immature woven bone can be seen (×50).
A B C D
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Figure 4. Histologic findings of experimental group 1 (0.05 mg/mL ErhBMP-2) at 8 weeks. (A) When compared to the 4 week healing group, 
more vascularization is evident in the 8-week healing group (arrowheads). The surgically created defect was almost completely closed. The 
particle size of the graft materials is dramatically reduced (white asterisk). Note that mature lamellar bone (black asterisk) is evident in the 
newly formed bone found in between graft materials (×12.5). (B) Defect margin area: both inflammatory cells and blood vessels can be ob-
served, as indicated by the arrows and the arrowhead, respectively. The black asterisk indicates matured lamellar bone (×50). (C) The Sch-
neiderian membrane: The Schneiderian membrane was also thicker than that of the 4 week healing group (×50). (D) Middle area: More ma-
ture lamellar bone is identified in newly formed bone found in between the graft materials (×50).
A B C D
Figure 5. Histologic findings of experimental group 2 (0.5 mg/mL ErhBMP-2) at 4 weeks. (A) The histologic findings were similar to those 
observed in experimental group 1 (0.05 mg/mL ErhBMP-2) at 4 weeks. Note that surgically created defect was completely closed (×12.5). (B) 
Defect margin area (×50). (C) The Schneiderian membrane (×50). (D) Middle area (×50).
A B C D
Figure 6. Histologic findings of experimental group 2 (0.5 mg/mL ErhBMP-2) at 8 weeks. (A) The histologic findings were similar to those 
observed in experimental group 1 (0.05 mg/mL ErhBMP-2) at 8 weeks. More vascularization (arrowheads) and matured lamellar bone (black 
asterisk) are also evident here (×12.5). (B) Defect margin area both inflammatory cells and blood vessels can be observed, as indicated by the 
arrow and the arrowhead, respectively. The black asterisk indicates matured lamellar bone (×50). (C) The Schneiderian membrane (×50). (D) 
Middle area (×50).
A B C D
graft materials, which can be seen to be still undergoing the 
mineralization process.
In general, when compared to the 4-week healing group, 
more vascularization is evident in the 8-week healing group 
in both experimental group 1 and group 2 (Figs. 4 and 6) The 
Schneiderian membrane was also slightly thickened with the 
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presence of inflammatory cells and blood vessels in the 
8-week healing group. The particle size of graft materials was 
also dramatically reduced. Instead, mature lamellar bone was 
identified in between the graft materials. It was also noted 
that the surgically created defects were almost completely 
closed in the 8-week healing group. 
DISCUSSION
The effectiveness of bone substitutes and dental implants 
has been evaluated through various sinus models [20-23]. 
Asai et al. [20] introduced the rabbit sinus model to under-
stand the mechanism of new bone formation in humans be-
cause the composition and mechanical properties of bone 
tissue in humans and rabbits are known to be very similar to 
each other [24]. Based on this study, researchers have used 
this rabbit sinus model to evaluate histomorphometric chang-
es of the bone after sinus grafting, assessing the effectiveness 
of various bone substitute materials. The purpose of the 
present study was to determine whether BCP with two dif-
ferent concentrations of ErhBMP-2 enhances new bone for-
mation in a standardized rabbit sinus model and to evaluate 
the concentration-dependent response of ErhBMP-2. In the 
present study, the standardized sinus model with the same 
shape and size of window was used, as introduced by De 
Souza Nunes et al. [25] to provide precisely the same condi-
tions to the control and the experimental groups and to min-
imize procedural errors. The degree of anatomical variation 
between individuals was also smaller in the rabbit sinus mod-
el than in larger animals, thereby enabling a consistent re-
production of defects in different individuals [16], as evidenced 
by the present histologic findings. According to Roberts and 
Breznak [26], the rabbit metabolic rate is known to be three 
to four times faster than that of humans. Thus, the 4-week 
healing group and 8-week healing group were selected on 
the assumption that a 4-week healing period and 8-week 
healing period correspond to a 3 to 4 months healing period 
and 6 to 8 months healing period in humans, respectively. 
The surgical sites were exposed by an extraoral approach, 
which enabled good visibility and accessibility to the surgical 
site as well as preservation of the Schneiderian membrane 
through delicate drilling and careful removal of the window. 
Therefore, taking the aforementioned factors into account, 
the standardized sinus augmentation model used in this study 
can be considered to be a valid study model in which various 
bone graft materials can be evaluated. 
In order to evaluate the volumetric change in new bone, 3D 
volumetric measurement of the augmented bone could have 
led to more accurate results; however, we used a two-dimen-
sional section of the window region for the comparison of 
new bone formation in the control group and experimental 
group. To minimize the error from this procedure, linear 
measurements including MAH, DDD, and CT volume were 
performed at the two-dimensional section of the window re-
gion using micro-CT. 
From histomorphometric analysis, it was found that in the 
4-week healing groups, new bone formation was statistically 
significantly greater in experimental group 1 than control 
group 1. Based on this result, it can be interpreted that in ex-
perimental group 1, more graft materials were substituted 
with new bone. In other words, bone graft materials coated 
with even low concentration of ErhBMP-2 (0.05 mg/mL) 
showed better osteoinductive potential than bone graft ma-
terials alone. Although the difference is not statistically sig-
nificant, bone graft materials coated with a high concentra-
tion of ErhBMP-2 (0.5 mg/mL) also showed better osteoin-
ductive potential than the control group. Thus, these findings 
demonstrate that ErhBMP induces rapid bone formation 
and remodeling at an earlier stage, and this is consistent with 
findings of a previous study [2] that used the rat calvarial de-
fect model. On the other hand, in the 4-week healing groups, 
the remaining graft was statistically significantly less in ex-
perimental group 1 than control group 1. This can be inter-
preted as showing that more of the bone graft material in ex-
perimental group 1 had been substituted with new bone, 
thereby showing less remaining graft material. Considering 
the fact that the amount of graft material applied to each 
group was the same, there might be no difference between 
experimental group 1 and group 2 in osteoinductive poten-
tial. This result is also supported by the results of the 8-week 
healing groups where MAH was statistically significantly 
greater in experimental group 1 than group 2, which can be 
interpreted as showing that the total amount of bone includ-
ing new bone and graft materials increased to some extent. 
However, since there was no significant difference in CT 
volume between experimental group 1 and group 2, it is dif-
ficult to conclude that a difference in osteoinductive poten-
tial between two groups is evident. 
In the 8-week healing groups, CT volume was statistically 
significantly greater in control group 1 than experimental 
group 1. However, there was not any difference between ex-
perimental group 1 and control group 1 in new bone forma-
tion and remaining graft material. This can be interpreted as 
showing that replacement of biomaterial with newly formed 
bone does not necessarily occur in a 1:1 ratio, which is in 
agreement with previous research [27]. In other words, the 
volume of bone produced in this case was greater than the 
volume of biomaterial absorbed. In the 8-week healing 
groups, the MAH in experimental group 1 was greater than 
experimental group 2. However, there was no significant dif-
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ference in CT volume. Therefore, the greater MAH in experi-
mental group 1 is difficult to interpret as ‘more new bone 
formation’ in experimental group 1 than group 2. 
Nevertheless, as new bone formation was statistically sig-
nificantly greater in experiment group 2 than control group 2, 
it seems that bone graft materials coated with a high concen-
tration of ErhBMP-2 (0.5 mg/mL) show better ongoing os-
teoinductive potential even in that late healing period. This 
could lead to an assumption that, although no significant 
difference between the low concentration of ErhBMP-2 (0.05 
mg/mL) and high concentration of ErhBMP-2 (0.5 mg/mL) 
in osteoinductive potential was found, the high concentration 
of ErhBMP-2 (0.5 mg/mL) can be more effective when long-
term osteoinductive potential is needed. 
In conclusion, within the limitations of this study, while 
BCP coated with ErhBMP-2 significantly enhanced osteoin-
ductive potential, a concentration-dependent response to os-
teoinductive potential was not found. 
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